Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space... Show more
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial-stage medical device company seeking to redefine endovascular procedures through robotics. Its flagship LIBERTY Endovascular Robotic System is the first U.S. Food and Drug Administration (FDA)-cleared, single-use, remotely operated robotic platform for peripheral endovascular procedures. The company estimates an initial U.S. addressable market of approximately 2.5 million peripheral endovascular procedures annually.
The strategic thesis centers on a differentiated economic model: because LIBERTY is disposable and single-use, it avoids the substantial capital expenditure and dedicated infrastructure historically required by multi-use surgical robots. This positioning could lower the barrier to entry for hospitals and ambulatory sites, potentially enabling broader, faster penetration than capital-intensive competitors. The company has also built a growing intellectual property portfolio, with patents granted across the U.S., China, Japan, and Israel, supporting long-term monetization in markets that accept FDA-cleared devices.
Structural risks remain. The company's commercial track record is short, and adoption depends on convincing hospital administrators and interventional radiologists to shift workflow toward a new robotic category. Competition from established robotics players and the need to demonstrate consistent clinical and economic value across diverse sites will be central to medium-term positioning.
Several developments could shape investor sentiment over the coming quarters. The planned Full Market Release of LIBERTY around the SIR conference in April 2026 is a pivotal milestone, as it transitions the company from a limited, controlled launch to broader commercial availability. Early adoption signals, such as the first hospital deployments, will be closely watched as evidence of real-world demand.
Recurring-order dynamics represent another catalyst. Because LIBERTY is a consumable, repeat purchases rather than one-time capital sales will be the key proof point for the model's scalability. Management has indicated that accumulating reorders and system-level approvals are central supports for the story.
Analyst activity has become more nuanced. While firms such as B. Riley Securities and Lucid Capital have maintained Buy ratings, both reduced their price targets, and Lucid Capital lowered its target to $3 from $4, citing near-term figures that remain modest. Citizens JMP initiated coverage with a Buy rating and a $2.50 target, while H.C. Wainwright has reiterated a higher $12 target. This dispersion reflects a market weighing long-term potential against slower-than-hoped adoption, making upcoming revenue disclosures and order commentary the most important near-term data points.
The company's trajectory is tied to broader healthcare economics. Elevated interest rates and ongoing capital-spending discipline among hospitals favor capital-light, consumable-based solutions such as LIBERTY, which avoid large upfront outlays. Conversely, slower capital cycles can still delay system-level approvals and adoption decisions as institutions scrutinize budgets.
Technology adoption trends in interventional radiology remain supportive, with growing interest in robotics that reduce physician radiation exposure and improve ergonomics. Regulatory climate is also material: the company's strategy of expanding into markets that accept FDA-cleared devices could accelerate international entry, while any shifts in FDA priorities or tariff policies on imports remain watch items. Inflation and hospital staffing pressures may further favor efficiency-enhancing tools, though reimbursement clarity will ultimately influence how quickly new procedures are embraced.
For traders seeking a forward-looking, data-driven view of MBOT and other instruments, Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help identify whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the next week or month. It is built to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad range of tradable instruments. The platform includes searchable prediction categories, historical context, and alert-oriented functionality to support ongoing monitoring. Consider exploring the Trend Prediction Engine to complement your own research and stay informed on evolving market signals.
Looking toward 2026 and beyond, the dominant theme is the transition from regulatory clearance to commercial scale. Success will be measured by the pace at which early interest converts into recurring orders, and by whether the Full Market Release broadens the installed base beyond early adopters. Cost-structure evolution is another focus: a consumable model carries attractive margin potential at scale but requires sufficient procedure volume to offset operating costs and support working capital.
Market expansion opportunities exist internationally, where acceptance of FDA-cleared devices and a growing patent portfolio could open new geographies. Competitive threats from incumbent robotics firms and emerging technologies will test LIBERTY's differentiation, while regulatory developments and reimbursement decisions will shape long-term addressable demand.
Analyst consensus reflects a mix of enthusiasm and caution. The average 12-month price target across surveyed firms sits in the mid-single-digit range, with a wide spread between conservative and more aggressive estimates. This dispersion underscores that near-term execution—rather than the technology's long-term promise—will likely determine how sentiment evolves. Investors monitoring the name will watch order metrics, hospital adoption announcements, and any updates to published analyst price targets as indicators of whether commercialization is tracking expectations.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SNAG | 5.00 | 0.65 | +14.94% |
| Leverage Shares 2x Long SNAP Daily ETF (SNAG) | |||
| TSLQ | 15.50 | -0.01 | -0.06% |
| Tradr 2X Short TSLA Daily ETF New Oct 2025 (TSLQ) | |||
| FJUL | 59.58 | -0.50 | -0.83% |
| FT Vest U.S. Equity Buffer ETF - July (FJUL) | |||
| UCIB | 35.25 | -0.48 | -1.36% |
| ETRACS CMCI Total Return ETN Series B (UCIB) | |||
| IMF | 52.27 | -0.79 | -1.49% |
| Invesco Managed Futures Strategy ETF (IMF) | |||
A.I.dvisor indicates that over the last year, MBOT has been loosely correlated with AGPU. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if MBOT jumps, then AGPU could also see price increases.
| Ticker / NAME | Correlation To MBOT | 1D Price Change % | ||
|---|---|---|---|---|
| MBOT | 100% | +6.92% | ||
| AGPU - MBOT | 37% Loosely correlated | -4.71% | ||
| BWAY - MBOT | 34% Loosely correlated | -2.98% | ||
| QSI - MBOT | 33% Loosely correlated | -4.72% | ||
| AIMD - MBOT | 32% Poorly correlated | +7.89% | ||
| CODX - MBOT | 31% Poorly correlated | -12.85% | ||
More | ||||
| Ticker / NAME | Correlation To MBOT | 1D Price Change % |
|---|---|---|
| MBOT | 100% | +6.92% |
| Medical/Nursing Services industry (138 stocks) | 5% Poorly correlated | -0.39% |
| Health Services industry (238 stocks) | 4% Poorly correlated | -1.42% |
a company, which specializes in the research, design, development and commercialization of micro-robotics assisted medical technologies
Industry MedicalNursingServices
The Aroon Indicator for MBOT entered a downward trend on November 02, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 248 similar instances where the Aroon Indicator formed such a pattern. In 222 of the 248 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MBOT as a result. In 70 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for MBOT turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 40 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBOT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBOT advanced for three days, in 150 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
MBOT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. MBOT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.082) is normal, around the industry mean (4.142). P/E Ratio (-4.440) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (263.158) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBOT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.